A5060855777- Renal Transplantation Outcomes and Treatments
- Tissue Engineering and Regenerative Medicine
- Transplantation: Methods and Outcomes
- Mesenchymal stem cell research
- Cardiac Structural Anomalies and Repair
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Renal Diseases and Glomerulopathies
- Cardiovascular Function and Risk Factors
- Hematopoietic Stem Cell Transplantation
- Complement system in diseases
- Electrospun Nanofibers in Biomedical Applications
- Circular RNAs in diseases
- Mechanical Circulatory Support Devices
- T-cell and B-cell Immunology
- Organ Donation and Transplantation
- Cytomegalovirus and herpesvirus research
- Organ and Tissue Transplantation Research
- Organ Transplantation Techniques and Outcomes
Leiden University Medical Center
2019-2023
Mesenchymal stromal cells (MSC) hold promise as a novel immune-modulatory therapy in organ transplantation. First clinical studies have used autologous MSCs; however, the use of allogeneic "off-the-shelf" MSCs is more sustainable for broad implementation, although with risk causing sensitization. We investigated safety and feasibility renal transplantation, using matching strategy that prevented repeated mismatches. Ten patients received two doses 1.5 × 10<sup>6</sup>/kg 6 months after...
Simultaneous pancreas-kidney transplantation (SPKT) replaces kidney function and restores endogenous insulin secretion in patients with diabetic nephropathy (DN). Here, we aimed to identify circulating long noncoding RNAs (lncRNAs) that are associated DN vascular injury the context of SPKT. Based on a pilot study literature-based selection injury-related lncRNAs, assessed 9 candidate lncRNAs plasma samples diabetes mellitus >35 mL/min/1.73 m2 (DM; n = 12), (n 14), SPKT 35), healthy controls...
Summary B cells have various functions, besides being plasma cell precursors. We determined the presence of intragraft at time acute rejection (AR) and looked for correlates involvement in peripheral blood. Renal biopsies AR or stable graft function were analysed cell-related gene expression, as well C4d staining. Peripheral blood subset distribution was time-points patients with controls, alongside serum human leucocyte antigen (HLA) antibodies. accompanied by CD20+ cells, elevated CD20...
Recently, the randomized phase‐II Triton study demonstrated that mesenchymal stromal cell (MSC) therapy facilitated early tacrolimus withdrawal in living donor kidney transplant recipients. The current sub‐study analyzed formation of de novo donor‐specific HLA antibodies (dnDSA) context degree eplet mismatches. At time protocol biopsy at 6 months, 7/29 patients (24%) MSC group and 1/27 patient (3.7%) control had developed dnDSA. In group, all dnDSA were anti‐HLA‐DQ; two anti‐DQ alone five...
Acute rejection (AR) of a kidney graft in renal transplant recipients is associated with microvascular injury dysfunction and, ultimately, failure. Circulating long noncoding RNAs (lncRNAs) may be suitable markers for vascular the context AR. Here, we first investigated effect AR after transplantation on local integrity and demonstrated that capillary density markedly decreased biopsies compared to pre-transplant biopsies. Subsequently, assessed circulating levels four lncRNAs (LNC-RPS24,...
Background After renal transplantation, there is a need of immunosuppressive regimens that effectively prevent allograft rejection while minimizing cardiovascular complications. This substudy the TRITON trial evaluated effects autologous bone marrow–derived mesenchymal stromal cells (MSCs) in transplant recipients. Methods and Results Renal recipients were randomized to MSC therapy, infused at weeks 6 7 after with withdrawal week 8 tacrolimus or standard dose. Fifty‐four patients (MSC...
Abstract Background After renal transplantation, there is a need for immunosuppressive regimens that effectively prevent allograft rejection, while minimizing cardiovascular side effects. The TRITON study the first randomized clinical trial tested strategy with autologous bone marrow derived mesenchymal stromal cell (MSC) therapy and complete withdrawal of calcineurin inhibitors (CNIs). combination MSC CNIs discontinuation was associated improved blood pression control regression left...